SPAC664.13 Antibody

What is SPAC664.13 and why is it studied in S. pombe?

SPAC664.13 is a systematic gene identifier in the S. pombe genome. Like other SPAC-designated genes (such as SPAC664.03 which encodes a component of the Paf1 complex), it represents a specific open reading frame located on chromosome I of the fission yeast Schizosaccharomyces pombe . Research on proteins encoded by SPAC-designated genes often focuses on understanding fundamental cellular processes including transcription regulation, chromatin modification, and nuclear-cytoplasmic trafficking.

What detection methods are recommended for SPAC664.13 antibody validation?

For proper validation of SPAC664.13 antibodies, multiple complementary techniques should be employed:

• Western Blotting: Following the protocol described in the literature, separate approximately 50μg of total protein via SDS-PAGE (8% acrylamide gel is commonly used for S. pombe proteins). Detection using appropriate secondary antibodies (anti-mouse-HRP at 1:2000 dilution) and image capture systems (such as ChemiDoc with ChemHi Sensitivity settings) can confirm specificity .

• Immunoprecipitation followed by Mass Spectrometry: This approach can validate antibody specificity by confirming the identity of the precipitated protein.

• Genetic Controls: Include appropriate negative controls such as deletion mutants where available, or positive controls with epitope-tagged versions of the protein of interest .

What are the recommended protocols for protein extraction from S. pombe for SPAC664.13 detection?

For optimal protein extraction when working with SPAC664.13 antibodies:

• Harvest 1.5×10^7 cells from exponentially growing cultures in appropriate media (such as YES) .

• Resuspend cell pellets in lysis buffer containing 50mM HEPES (pH 7.6), 150mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 1mM PMSF, and protease inhibitor cocktail .

• Add approximately 200μl of sterile glass beads and lyse cells at 4°C using a mini-beat beater (4×30s with 1-minute rests on ice) .

• Transfer lysates to 1.5mL tubes and centrifuge at maximum speed for 15 minutes to collect the protein fraction .

• For certain applications, additional sonication may be performed using a Bioruptor waterbath sonicator (30s ON/OFF cycles with 2-minute rest on ice after 10 minutes) .

How can I optimize chromatin immunoprecipitation (ChIP) protocols for SPAC664.13 antibodies in S. pombe?

Optimizing ChIP protocols for SPAC664.13 antibodies requires careful consideration of several parameters:

• Crosslinking Optimization: Fix 1.5×10^7 cells with 1% formaldehyde for 30 minutes at room temperature. Stop crosslinking with 125mM glycine (pH 2.5) .

• Chromatin Preparation: After cell lysis, sonicate chromatin for 20 minutes using a Bioruptor waterbath sonicator with 30-second ON/OFF cycles. Include 2-minute rests on ice after 10 minutes of sonication to prevent overheating and protein denaturation .

• Immunoprecipitation Conditions: Incubate sonicated chromatin with antibody-coupled beads (15μl of protein G Dynabeads recommended) for 2-3 hours at 4°C with constant rocking .

• Washing Stringency: Perform successive washes with increasing stringency buffers:

  • Lysis buffer + 0.1% SDS

  • Lysis buffer + 0.1% SDS + 500mM NaCl

  • LiCl buffer (10mM Tris-HCl pH 7.5, 1mM EDTA, 250mM LiCl, 0.5% sodium deoxycholate, 0.5% NP-40)

  • TE buffer (10mM Tris-HCl pH 7.5, 1mM EDTA)

• Elution and Crosslink Reversal: Elute chromatin with 100μl elution buffer (50mM Tris-HCl pH 7.5, 10mM EDTA, 1% SDS) at 65°C for 30 minutes .

How can I apply the anchor-away technique to study SPAC664.13 protein function?

The anchor-away technique provides a powerful approach for studying SPAC664.13 protein function through rapid and conditional inactivation:

• Base Strain Construction: Generate base strains containing fkh1Δ tor1-SE mutations and an integrated cytoplasmic anchor (e.g., Rpl13-2FKBP12) as described for similar S. pombe proteins .

• Tagging Strategy: Tag SPAC664.13 with FRB or FRB-GFP using appropriate plasmids (e.g., pLD115 or pLD116 with NatMX6 marker) .

• Assay Strain Generation: Construct the assay strain either by direct transformation or genetic crossing as illustrated in previous work with nuclear proteins .

• Functional Assessment: Verify functionality of the tagged protein by confirming normal growth and absence of drug sensitivity. Test rapamycin-dependent depletion by monitoring viability and phenotypic changes upon rapamycin addition .

• Visualization: For FRB-GFP tagged constructs, monitor protein localization using fluorescence microscopy with appropriate settings (e.g., 18 z-sections at 0.3μm using GFP/mCherry polychroic mirror and oil-immersion objective) .

What factors should be considered when troubleshooting non-specific binding of SPAC664.13 antibodies in co-immunoprecipitation experiments?

Several factors can contribute to non-specific binding in co-IP experiments with SPAC664.13 antibodies:

• Cell Extract Preparation: Ensure optimal cell lysis conditions by comparing mechanical lysis methods (glass beads vs. cryogenic grinding) and buffer compositions (varying detergent concentrations and salt concentrations) .

• Pre-clearing Strategy: Implement a pre-clearing step using appropriate control beads (without antibody) to reduce non-specific binding components.

• Binding Conditions Optimization: Test a matrix of conditions varying:

  • Antibody concentration

  • Incubation time (2-3 hours vs. overnight)

  • Temperature (4°C is standard)

  • Salt concentration (150-500mM NaCl range)

• Washing Stringency: Implement a step-gradient washing approach with increasing detergent or salt concentrations to identify optimal specificity without losing genuine interactions .

• Controls: Always include appropriate negative controls (such as untagged strains or IgG-only precipitations) and positive controls (known interacting partners when available) .

How do mutations in Paf1 complex components affect SPAC664.13 antibody-based experiments?

Mutations in Paf1 complex components can significantly impact SPAC664.13 antibody-based experiments, as demonstrated by research with other S. pombe proteins:

When working with strains carrying these mutations, researchers should:

• Validate antibody specificity in each mutant background separately

• Adjust extraction conditions to account for potential changes in protein complex stability

• Consider complementary approaches (e.g., epitope tagging) to confirm antibody-based results

What are the best approaches for multiplexed detection of SPAC664.13 and other S. pombe proteins?

For multiplexed detection of SPAC664.13 and other S. pombe proteins:

• Antibody Selection: Ensure primary antibodies are raised in different host species to prevent cross-reactivity of secondary antibodies.

• Sequential Immunoblotting: For western blot detection of multiple proteins on the same membrane:

  • Strip and reprobe membranes between detections

  • Use chemiluminescent substrates with different emission spectra

  • Employ fluorescently-labeled secondary antibodies for simultaneous detection

• Microscopy-Based Multiplex Detection: For co-localization studies:

  • Use spectrally distinct fluorophores for differently tagged proteins

  • Employ the DeltaVision core microscope approach with z-sectioning (18 sections at 0.3μm) for accurate spatial resolution

  • Reconstruct projected images using appropriate software (such as softWoRx 5.5)

• Mass Spectrometry Integration: Combine immunoprecipitation with MS analysis to identify multiple interacting partners simultaneously.

How should controls be designed for SPAC664.13 antibody specificity validation in mutant S. pombe strains?

Comprehensive control design for SPAC664.13 antibody validation should include:

• Genetic Controls:

  • Gene deletion strain (if SPAC664.13 is non-essential)

  • Partial deletion or domain mutants

  • Epitope-tagged versions of SPAC664.13 that can be detected with commercial antibodies (e.g., GFP, TAP, myc tags)

• Expression Controls:

  • Strains with SPAC664.13 under inducible promoters (such as nmt1) to create gradient expression levels

  • Overexpression constructs for positive control signals

• Cross-Reactivity Assessment:

  • Testing antibody in strains with deletions of proteins with similar domains

  • Preabsorption of antibody with recombinant target protein

• Application-Specific Controls:

  • For ChIP experiments: include no-antibody controls and unrelated antibody controls

  • For immunofluorescence: include peptide competition assays

What are the critical parameters for optimizing SPAC664.13 protein extraction from different S. pombe growth phases?

Protein extraction from different growth phases requires specific adjustments:

• Log Phase Cultures:

  • Harvest 1.5×10^7 cells at OD ≈ 0.8

  • Standard lysis buffer composition is sufficient

  • Brief sonication (20 minutes using Bioruptor) efficiently releases proteins

• Stationary Phase Cultures:

  • Increase cell number to 3×10^7 to compensate for thickened cell walls

  • Enhance mechanical disruption (6×30s with beat beater instead of 4×30s)

  • Add additional protease inhibitors to counteract increased protease activity

• Nitrogen-Starved Cells:

  • Modify lysis buffer with higher detergent concentration (1.5% Triton X-100)

  • Include phosphatase inhibitors to preserve modification states

  • Extend bead beating time for more efficient breakage

• Extraction Buffer Optimization By Growth Phase:

How can I differentiate between specific and non-specific binding when using SPAC664.13 antibodies in different S. pombe genetic backgrounds?

To differentiate between specific and non-specific binding across different genetic backgrounds:

• Titration Analysis: Perform antibody dilution series on samples from different genetic backgrounds to identify concentration thresholds where specificity is maintained.

• Competition Assays: Pre-incubate antibody with purified recombinant SPAC664.13 protein before immunodetection to block specific binding sites.

• Epitope Mapping: Determine if genetic background affects the epitope recognized by your antibody by testing against truncated versions of the protein.

• Quantitative Analysis: Plot signal-to-noise ratios across different genetic backgrounds to establish detection thresholds specific to each background.

• Cross-Validation Approach: Confirm findings using orthogonal methods such as mass spectrometry or alternative antibodies targeting different epitopes of the same protein .

What strategies can resolve contradictory data between SPAC664.13 ChIP-seq and immunofluorescence localization patterns?

Resolving contradictions between ChIP-seq and immunofluorescence data requires systematic troubleshooting:

• Epitope Accessibility Analysis:

  • Test if fixation conditions affect epitope exposure differently in each technique

  • Compare native versus cross-linked ChIP approaches

  • Evaluate multiple antibodies targeting different regions of SPAC664.13

• Cell Cycle Considerations:

  • Synchronize cells to determine if discrepancies are related to cell cycle-specific localization

  • Perform time-course experiments following cell cycle progression

• Technique-Specific Controls:

  • For ChIP-seq: include spike-in controls and perform quantitative PCR validation of selected loci

  • For immunofluorescence: compare formaldehyde-fixed versus methanol-fixed samples and optimize imaging parameters

• Orthogonal Validation:

  • Employ the anchor-away technique with FRB-GFP tagging to monitor protein dynamics in live cells

  • Use biochemical fractionation to assess subcellular distribution quantitatively

How can the anchor-away technique be combined with SPAC664.13 antibody detection for studying protein interaction dynamics?

Combining anchor-away with antibody detection creates a powerful approach for studying SPAC664.13 interaction dynamics:

• Experimental Design:

  • Tag SPAC664.13 with FRB-GFP using appropriate plasmids (pLD116)

  • Generate strains containing integrated Rpl13-2FKBP12 cytoplasmic anchor

  • Ensure inclusion of fkh1Δ tor1-SE mutations for rapamycin sensitivity

• Time-Course Analysis Protocol:

  • Split cultures and add rapamycin (5μg/mL final concentration) or DMSO control

  • Collect samples at defined time points (5, 15, 30, 60 minutes) post-treatment

  • Process parallel samples for:
    a) Microscopy to visualize protein relocalization
    b) Co-immunoprecipitation to assess protein interaction changes
    c) ChIP to monitor chromatin association dynamics

• Quantification Approach:

  • For microscopy: measure nuclear/cytoplasmic signal ratio over time

  • For protein interactions: normalize co-precipitated protein to total target protein

  • For ChIP: calculate enrichment relative to input and normalize to control regions

• Controls:

  • Include wild-type tor1 strains with anchor to confirm rapamycin-specificity

  • Monitor growth and viability to ensure observed effects precede general cellular toxicity

What are the best practices for preserving post-translational modifications when working with SPAC664.13 antibodies?

Preserving post-translational modifications (PTMs) requires specialized approaches:

• Extraction Buffer Optimization:

  • Include specific inhibitors based on the PTM of interest:

    • Phosphorylation: 50mM NaF, 10mM Na₃VO₄, 10mM β-glycerophosphate

    • Ubiquitination: 10mM N-ethylmaleimide, deubiquitinase inhibitors

    • Acetylation: 5mM sodium butyrate, 1μM trichostatin A

• Sample Handling:

  • Maintain samples at 4°C throughout processing

  • Minimize time between cell harvest and protein extraction

  • Use low-binding tubes to prevent differential adsorption of modified proteins

• Detection Strategy:

  • For phosphorylation-specific detection, consider λ-phosphatase controls

  • For ubiquitination studies, include proteasome inhibitors during culture

  • For acetylation analysis, compare samples with/without HDAC inhibitors

• Validation Approach:

  • Use modification-specific antibodies (e.g., phospho-specific) in parallel with general SPAC664.13 antibodies

  • Confirm PTM identity with mass spectrometry analysis

  • Compare wild-type samples with mutants in relevant modification pathways

How do SPAC664.13 antibody detection methods compare across different model organisms?

While SPAC664.13 is specific to S. pombe, comparative approaches with homologous proteins in other organisms can be informative:

• Cross-Species Reactivity Assessment:

  • Test SPAC664.13 antibodies against potential homologs in S. cerevisiae and other yeasts

  • Compare epitope conservation using sequence alignment tools

  • Validate cross-reactivity using recombinant proteins from multiple species

• Methodological Adaptations Required:

• Comparative Workflow Development:

  • Establish unified protocols that work across species with minimal modifications

  • Create benchmark datasets for antibody performance metrics

  • Develop normalization strategies to enable quantitative cross-species comparisons

What correlations exist between SPAC664.13 protein levels and transcriptional changes in various S. pombe mutants?

Understanding protein-transcript correlations requires integrated analysis:

• Experimental Design for Correlation Studies:

  • Collect parallel samples for protein analysis (Western blot) and transcriptome analysis (RNA-seq)

  • Include diverse mutant backgrounds, particularly those affecting:

    • Chromatin modifiers

    • Transcription factors

    • RNA processing factors

    • Protein stability regulators

• Mutant Impacts to Consider:

  • Paf1 complex mutations (G102S, Q170Stop in SPAC664.03; E435K, A439T in SPBC651.09c) may affect transcript levels without proportional protein changes

  • RNA processing mutations (in components like Yth1, Rcd1, Pcm1) might alter transcript stability without affecting translation efficiency

  • Investigate correlations in nonsense-mediated decay pathway mutants (e.g., Upf2 S726I) that may differentially affect transcript and protein levels

• Quantitative Analysis Approach:

  • Calculate transcript-to-protein ratios across different mutants

  • Identify conditions where ratios deviate significantly from wild-type

  • Perform time-course analyses to detect temporal disconnects between transcriptional and translational changes